Victoria Brown - Apellis Pharmaceuticals Senior President
| APLS Stock | USD 47.46 0.03 0.06% |
President
Victoria Brown is Senior President of Apellis Pharmaceuticals
| Age | 44 |
| Address | 100 Fifth Avenue, Waltham, MA, United States, 02451 |
| Phone | 617 977 5700 |
| Web | https://www.apellis.com |
Apellis Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.4173) % which means that it has lost $0.4173 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.9014) %, meaning that it created substantial loss on money invested by shareholders. Apellis Pharmaceuticals' management efficiency ratios could be used to measure how well Apellis Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.7 in 2024. Return On Capital Employed is likely to drop to -1 in 2024. At this time, Apellis Pharmaceuticals' Other Current Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 205.1 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 18.2 M in 2024.Management Performance
| Return On Equity | -2.9 | ||||
| Return On Asset | -0.42 |
Apellis Pharmaceuticals Leadership Team
Elected by the shareholders, the Apellis Pharmaceuticals' board of directors comprises two types of representatives: Apellis Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Apellis. The board's role is to monitor Apellis Pharmaceuticals' management team and ensure that shareholders' interests are well served. Apellis Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Apellis Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Timothy Sullivan, CFO, Treasurer | ||
| Cedric MD, President, CoFounder | ||
| Meredith Kaya, Investor President | ||
| Adam Townsend, Chief Commercial Officer | ||
| James CPA, Corporate VP | ||
| Karen Lewis, Chief Officer | ||
| Nur Nicholson, Chief Officer | ||
| JD Esq, General Counsel | ||
| MBA JD, CoFounder Director | ||
| Pr MD, Head Board | ||
| David Acheson, Senior Commercial | ||
| Lukas MD, Chief Officer | ||
| Mark Delong, Chief Officer | ||
| Federico MD, CoFounder Officer | ||
| Victoria Brown, Senior President | ||
| Pascal Deschatelets, CoFounder Officer | ||
| Jeffrey Eisele, Chief Officer |
Apellis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Apellis Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.9 | ||||
| Return On Asset | -0.42 | ||||
| Profit Margin | (1.33) % | ||||
| Operating Margin | (0.58) % | ||||
| Current Valuation | 5.48 B | ||||
| Shares Outstanding | 121.29 M | ||||
| Shares Owned By Insiders | 13.14 % | ||||
| Shares Owned By Institutions | 95.98 % | ||||
| Number Of Shares Shorted | 10.67 M | ||||
| Price To Earning | (6.94) X |
Pair Trading with Apellis Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Apellis Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Apellis Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Apellis Stock
| 0.76 | EGRX | Eagle Pharmaceuticals Earnings Call This Week | PairCorr |
| 0.76 | JNJ | Johnson Johnson Financial Report 18th of July 2024 | PairCorr |
Moving against Apellis Stock
| 0.74 | CGC | Canopy Growth Corp Financial Report 27th of June 2024 | PairCorr |
| 0.74 | QLI | Qilian International | PairCorr |
| 0.74 | SNDL | SNDL Inc Earnings Call This Week | PairCorr |
| 0.67 | IMCC | Im Cannabis Corp Earnings Call This Week | PairCorr |
| 0.61 | PAHC | Phibro Animal Health Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Apellis Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Apellis Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Apellis Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Apellis Pharmaceuticals to buy it.
The correlation of Apellis Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Apellis Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Apellis Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Apellis Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Apellis Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Apellis Stock please use our How to Invest in Apellis Pharmaceuticals guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Complementary Tools for Apellis Stock analysis
When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |
Is Apellis Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Apellis Pharmaceuticals. If investors know Apellis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Apellis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.45) | Revenue Per Share 3.342 | Quarterly Revenue Growth 5.459 | Return On Assets (0.42) | Return On Equity (2.90) |
The market value of Apellis Pharmaceuticals is measured differently than its book value, which is the value of Apellis that is recorded on the company's balance sheet. Investors also form their own opinion of Apellis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Apellis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Apellis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Apellis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Apellis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Apellis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Apellis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.